(Q40667276)

22 September 2017

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy (English)

1 reference

22 September 2017

phase II clinical trial

0 references

1 reference

1 reference

6

P H Wiernik

1 reference

22 September 2017

A I Einzig

1

1 reference

22 September 2017

L M Schuchter

2

1 reference

22 September 2017

A Recio

3

1 reference

22 September 2017

S Coatsworth

4

1 reference

22 September 2017

R Rodriquez

5

1 reference

22 September 2017

1 June 1996

1 reference

22 September 2017

1 reference

22 September 2017

13

1 reference

22 September 2017

2

1 reference

22 September 2017

111-117

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02993861

22 September 2017

0 references

cites work

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02993861

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02993861

Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients

21 January 2018

1 reference

12 December 2020

Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer

1 reference

12 December 2020

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

12 December 2020

Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma.

1 reference

12 December 2020

Chemotherapy of malignant melanoma

1 reference

12 December 2020

Clinical drug development: an analysis of phase II trials, 1970-1985

1 reference

12 December 2020

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

12 December 2020

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

1 reference

12 December 2020

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

1 reference

12 December 2020

DTIC (NSC-45388) in malignant melanoma: a perspective

1 reference

12 December 2020

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

12 December 2020

A phase II trial of taxol in metastatic melanoma

1 reference

12 December 2020

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

12 December 2020

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer

1 reference

12 December 2020

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

12 December 2020

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Survival and prognostic factors of patients with skin melanoma. A regression-model analysis based on nationwide cancer registry data

1 reference

12 December 2020

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Results with methyl-CCNU and DTIC in metastatic melanoma

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

12 December 2020

Phase I trial of Taxotere: five-day schedule

1 reference

12 December 2020

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02993861

1 reference

Dimensions Publication ID

22 September 2017

1026370951

0 references

Fatcat ID

release_zhaskitmoberphnueowlehjgvu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zhaskitmoberphnueowlehjgvu

24 November 2022

mapped directly with Wikidata item

1 reference